Untargeted metabolomic analysis reveals different metabolites associated with response to mepolizumab and omalizumab in asthma.
Tanawin NopsoponYulu ChenQingwen ChenCraig E WheelockScott T WeissMichael J McGeachieJessica Lasky-SuAyobami T AkenroyePublished in: ERJ open research (2024)
This study identifies distinct metabolites associated with response to mepolizumab and omalizumab, with androgenic steroids associated with response to both mepolizumab and omalizumab.